Amikacin News and Research RSS Feed - Amikacin News and Research

Researchers report that predominant CA-MRSA strain migrated from sub-Saharan Africa

Researchers report that predominant CA-MRSA strain migrated from sub-Saharan Africa

The predominant strain of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infecting people in Europe, the Middle East and northern Africa derived from a single sub-Saharan ancestor, a team of international researchers reported this week in mBio-, the online open-access journal of the American Society for Microbiology. [More]
Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar Therapeutics announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigator Seema Nagpal, M.D., Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford School of Medicine. [More]

Cystic fibrosis market estimated to reach $4.5 billion in 2019

Reportbuyer.com has added a new market research report: Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth [More]
Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Insmed Incorporated today reported results from the Company's phase 2 clinical trial of ARIKAYCETM, or liposomal amikacin for inhalation, for the treatment of patients with treatment resistant nontuberculous mycobacterial (NTM) lung infections. [More]
Three rapid diagnostic tests could be used to diagnose drug resistance in TB

Three rapid diagnostic tests could be used to diagnose drug resistance in TB

Results of a new study suggest that three new diagnostic tests could each be used to successfully diagnose drug resistance in tuberculosis (TB) patients in a quarter of the time taken by the current method. [More]
Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Nektar Therapeutics (NASDAQ: NKTR) today announced that enrollment is complete in the pivotal clinical study of etirinotecan pegol (NKTR-102) in patients with metastatic breast cancer. [More]
Patient enrollment underway in Phase III trial program to evaluate amikacin inhalation solution

Patient enrollment underway in Phase III trial program to evaluate amikacin inhalation solution

Bayer HealthCare Pharmaceuticals Inc. announced today that patient enrollment is underway in its global Phase III trial program to evaluate the efficacy and safety of adjunctive aerosolized BAY41-6551 versus aerosolized placebo in the treatment of intubated and mechanically ventilated patients with Gram-negative pneumonia receiving standard of care intravenous antibiotics. [More]
Specific therapy may cut pneumonia mortality in HIV babies

Specific therapy may cut pneumonia mortality in HIV babies

The high mortality rate associated with acute severe pneumonia-related respiratory failure in infants exposed to or infected with HIV can be reduced to 30% if a treatment plan involving antibiotics, ventilation, and fluid restriction is used, researchers report. [More]
New approach can design antibiotics that kill even 'superbugs'

New approach can design antibiotics that kill even 'superbugs'

The world needs new antibiotics to overcome the ever increasing resistance of disease-causing bacteria - but it doesn't need the side effect that comes with some of the most powerful ones now available: hearing loss. Today, researchers report they have developed a new approach to designing antibiotics that kill even "superbugs" but spare the delicate sensory cells of the inner ear. [More]
Insmed initiates patient screening for ARIKACE phase 2 NTM lung disease trial

Insmed initiates patient screening for ARIKACE phase 2 NTM lung disease trial

Insmed Incorporated, a biopharmaceutical company, today announced that it has begun screening patients for its U.S. phase 2 clinical trial, Treatment with ARIKACE to Realize Greater Efficacy Trial (TARGET-NTM), of ARIKACE (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease. [More]
Insmed fourth quarter revenues increase to $1.4 million

Insmed fourth quarter revenues increase to $1.4 million

Insmed Incorporated, a biopharmaceutical company, today reported results for the fourth quarter and fiscal year ended December 31, 2011. [More]
Insmed third quarter revenues decrease to $0.4 million

Insmed third quarter revenues decrease to $0.4 million

Insmed Incorporated, a biopharmaceutical company, today reported financial results for the third quarter and nine-months ended September 30, 2011. [More]

Insmed second quarter revenues decrease to $1.0 million

Insmed Incorporated, a biopharmaceutical company, today reported results for the second quarter and six-months ended June 30, 2011. [More]

Insmed receives FDA clinical hold order for ARIKACE phase 3 trials in CF and NTM

Insmed Incorporated, a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that the agency has placed a clinical hold on Insmed's phase 3 clinical trials for ARIKACE in Cystic Fibrosis (CF) patients with Pseudomonas lung infections and patients with non-tuberculous mycobacterial (NTM) lung disease. [More]

Insmed first quarter revenues decrease to $1.6 million

Insmed Incorporated, a biopharmaceutical company, today reported results for the first quarter ended March 31, 2011. [More]
FDA clears Insmed IND for ARIKACE Phase 3 clinical trial in nontuberculous mycobacteria lung infections

FDA clears Insmed IND for ARIKACE Phase 3 clinical trial in nontuberculous mycobacteria lung infections

Insmed Incorporated, a biopharmaceutical company, announced today that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of ARIKACEā„¢ (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung infections has been cleared by the U.S. Food and Drug Administration (FDA). [More]
Scientists find antibiotic-resistant bacteria in seven species of sharks and redfish

Scientists find antibiotic-resistant bacteria in seven species of sharks and redfish

Scientists have found antibiotic-resistant bacteria in seven species of sharks and redfish captured in waters off Belize, Florida, Louisiana and Massachusetts. Most of these wild, free-swimming fish harbored several drug-resistant bacterial strains. [More]
Scientists awarded $3.9M grant to study how XDR-TB transmitted in rural South Africa

Scientists awarded $3.9M grant to study how XDR-TB transmitted in rural South Africa

The National Institutes of Health has awarded scientists at Albert Einstein College of Medicine of Yeshiva University a five-year, $3.9 million grant to study how extensively drug-resistant tuberculosis is transmitted in rural South Africa. The findings could alter public health approaches for controlling the XDR-TB epidemic in the developing world. [More]
USPTO issues composition of matter patent for Transave's ARIKACE

USPTO issues composition of matter patent for Transave's ARIKACE

Transave Inc. today announced that the United States Patent and Trademark Office has issued an important composition of matter patent (U.S. Patent No. 7,718,189) for liposomal aminoglycoside formulations including its lead compound, ARIKACEā„¢ (liposomal amikacin for inhalation). The company expects that the patent will provide exclusivity for ARIKACE until October 1, 2026. [More]
WHO estimates 440 000 MDR-TB cases in 2008

WHO estimates 440 000 MDR-TB cases in 2008

In some areas of the world, one in four people with tuberculosis (TB) becomes ill with a form of the disease that can no longer be treated with standard drugs regimens, a World Health Organization (WHO) report says. [More]